FDA approves Covid breathalyzer that can detect cases in three minutes
Device can only be operated by trained professionals
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Food and Drug Administration has granted emergency use authorisation to a device that takes a sample of someone’s breath and can identify positive Covid tests in less than three minutes, the agency announced on Thursday.
The InspectIR Covid-19 Breathalyzer, which is only allowed to be operated by a trained professional, returns results faster than common at-home tests, according to its creators.
"The FDA continues to support the development of novel COVID-19 tests with the goal of advancing technologies that can help address the current pandemic and better position the U.S. for the next public health emergency," Dr Jeff Shuren, the FDA’s top COVID-19 testing official, said in a statement.
The marks the first time the agency has approved a breath-based test for use in the US.
The machine is about the size of a carry-on suitcase, and is designed for use in medical settings or at testing sites.
Current capacity suggests 100 InspectIRs can be made a week, with each device able to test up to 160 samples a day.
People being tested use a disposable sanitised straw to blow their sample into the device, using about the same amount of air required to inflate a small balloon, according to InspectIR.
The FDA has been studying the technology since 2020.
A study of the breathalyzer’s effectiveness found that presented with 2,409 samples, a mix of those with and without symptoms, the device spotted more than 90 per cent of cases with a false positive rate lower than 1 per cent.
The agency says breath tests should still be confirmed by a molecular test, mirroring its advice on the radiply proliferating market of at-home Covid tests.
InspectIR, which uses similar technology to screen people for drug use, argues this less-invasive test platform will assist companies in getting back to work.
"In less than three (3) minutes, our device(s) can tell if a person may be actively infected and precluded from entrance/admission to a facility. The only way to ensure a true safety protocol is to understand if people are well enough to be there ‘right now,’" the company’s president wrote in a 2021 post.
Public health officials have faulted the US for its inadequate Covid testing infrastructure and data, and lack of long-term, sustained efforts to monitor the disease.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments